Strm.Bio

Pre-clinical biotech company developing extracellular vesicles (EVs) as a vector for gene therapy delivery

Strm.Bio is a pre-clinical biotechnology company founded in 2019 by Jonathan Thon, PhD in Cambridge, MA. Joined by a seasoned team of development professionals, the company is leveraging extracellular vesicles (EVs) as a vector for gene therapy delivery, initially to the bone marrow. This new modality seeks to successfully deliver in vivo gene therapies by overcoming obstacles often limiting viral vectors and lipid nanoparticles. Naturally occurring EVs home to the bone marrow (avoiding un-targeted distribution); have low risk of immunogenicity which allows for repeat dosing, have larger payload capacities, and are easier to manufacture. CRISPR–Cas9, base editing, and prime editing are reducing bottlenecks in the gene editing process leaving gene delivery as an important challenge to be resolved. STRM.BIO is initially focused on the major unmet need which resides at the intersection of gene therapy and rare blood diseases.